Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. Allows Supplement Weight-Loss Claims Little Wiggle Room

This article was originally published in The Tan Sheet

Executive Summary

As resolution season arrives, the advertising watchdog underscores the rules for weight-loss claims and testimonials. Boots Pharmaceuticals’ Carb Control made a common unsubstantiated diet aid claim – binding fats in the stomach so they are not absorbed by the body, helping users shed pounds, the agency says.

You may also be interested in...



Demand For “Prediabetes” Supplements Exposes Marketing Risks

Navigating legally among claims for prediabetes or blood sugar levels is tricky. Experts discuss what keeps a claim legal and what crosses the line, and spotlight other disease categories that can get firms in trouble if claims are not crafted properly.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel